**University of
Zurich^{UZH}**

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2015

Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: a case report and review of the literature

Innenfeld Arciénega, Isabel ; Imesch, Patrick ; Fink, Daniel ; Dedes, Konstantin J

Abstract: Metastatic breast cancer is considered an incurable disease. Targeted treatments against the human epidermal growth factor receptor 2 (HER2), however, significantly improve survival in patients with metastatic HER2-positive breast cancer. Some patients may respond with prolonged complete remission. Evidence on safety of long-term trastuzumab and risk of relapse after trastuzumab cessation is limited. We present a case of an 81-year-old patient with HER2-amplified metastatic breast cancer (MBC) in the liver. Following taxane-based chemotherapy in combination with trastuzumab after local treatment resulted in a complete radiological remission after 21 months of trastuzumab maintenance therapy. The patient remains in complete remission 6 years later and continues to receive trastuzumab as maintenance therapy. Prolonged remission in cases with complete response under trastuzumab-based regimens for metastatic HER2-positive breast cancer can be observed in some patients. Reviewing the few available cases published in the literature, these patients share some common characteristics: hormone receptor negative disease and metastases to the liver. There is no evidence that trastuzumab maintenance treatment can be safely interrupted after a certain time period.

DOI: <https://doi.org/10.1007/s11523-014-0350-9>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-106138>

Journal Article

Accepted Version

Originally published at:

Innenfeld Arciénega, Isabel; Imesch, Patrick; Fink, Daniel; Dedes, Konstantin J (2015). Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: a case report and review of the literature. *Targeted oncology*, 10(2):297-301.

DOI: <https://doi.org/10.1007/s11523-014-0350-9>

Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: a case report and review of the literature.

Abstract

Introduction: Metastatic breast cancer is considered an incurable disease. Targeted treatments against the human epidermal growth factor receptor 2 (HER2), however, significantly improve survival in patients with metastatic HER2-positive breast cancer. Some patients may respond with prolonged complete remission. Evidence on safety of long-term trastuzumab and risk of relapse after trastuzumab cessation are limited.

Case presentation: We present a case of an 81-year-old patient with HER2-amplified metastatic breast cancer (MBC) in the liver. Following taxane-based chemotherapy in combination with trastuzumab after local treatment resulted in a complete radiological remission after 21 months of trastuzumab maintenance therapy. The patient remains in complete remission 6 years later and continues to receive trastuzumab as maintenance therapy.

Conclusion: Prolonged remission in cases with complete response under trastuzumab based regimens for metastatic HER2-positive breast cancer can be observed in some patients. Reviewing the few available cases published in the literature, these patients share some common characteristics: hormone receptor negative disease and metastases to the liver. There is no evidence that trastuzumab maintenance treatment can be safely interrupted after a certain time period.

Introduction

Trastuzumab added to standard chemotherapy has improved disease-free and overall survival (OS) among patients with HER2-amplified metastatic breast cancer (MBC) [1]. However HER2-amplified MBC is an aggressive breast cancer subtype, and despite the development of anti-HER2 targeted treatments, the majority of patients progress within 12 to 18 months [2,3]. Before the use of trastuzumab the natural course of this subtype had a poor prognosis. Due to the use of trastuzumab, the prognosis of hormone-receptor (HR)-negative/HER2-positive disease has significantly improved and OS even largely exceeds the one of HR-negative/HER2-negative disease [4]. In HR-positive disease, the results are controversial: whereas Dawood et al. show a similar OS between HER2-positive and HER2-negative subtypes, some say the OS of HER2-positive subtypes exceeds the OS of HER2-negative subtypes [5]. Generally, the OS of estrogen-receptor (ER)-positive/HER2-positive breast cancer have the best prognosis [5]. Only very few patients with a HER2-amplified MBC experience a prolonged remission. This case report describes a patient with a primary metastatic HR-negative/HER2-positive breast cancer. 6 years after locoregional and systemic treatment with paclitaxel and trastuzumab she remains in complete remission under trastuzumab maintenance therapy.

Case presentation

We present the case of an 81-year-old woman with primary metastatic HER2-positive breast cancer. Two liver metastases in segment IVa and VII measuring 3.3cm each (Figure 1) were detected in radiological staging after segmentectomy and axillary lymph node resection for her pT2 (32mm) pN2a (5/15) G3 ER/PR negative HER2-positive breast cancer. Postoperative chemotherapy with 4 cycles of paclitaxel (80mg/m² day 1, 8 and 15) and trastuzumab weekly (4 mg/kg loading dose followed by 2 mg/kg maintenance dose weekly) were administered. Complete radiological response and a non-pathological CA15-3 value were obtained after 21 months of trastuzumab maintenance treatment. The patient remains in complete remission 6 years after primary treatment of metastatic disease and continues to receive trastuzumab as maintenance therapy. Despite cardiovascular comorbidities such as arterial hypertension, hyperlipidemia, an Activated Protein C Resistance with recurrent deep vein thrombosis and a family history of myocardial infarct there were no morphological or functional cardiac changes during the trastuzumab therapy.

Discussion

HER2-targeted therapies have significantly improved disease-free interval and overall survival in HER2-amplified BC, which was associated with an aggressive biological behavior and a shorter disease-free interval and OS [6,7]. Trastuzumab however has improved the clinical outcome of patients with HER2-amplified BC beyond that of certain HER2-negative subtypes [8,4,9]. First-line treatment for HER2-amplified MBC commonly contains a taxane-based monochemotherapy regimen in combination with single or dual HER2 blockage [10,6,1]. Currently approved anti-HER2 directed drugs for the treatment of HER2-positive MBC in the United States are: anti-HER2 monoclonal antibodies, such as trastuzumab, pertuzumab and ado-trastuzumab emtansine and lapatinib, an inhibitor of HER2 and EGFR. Recently, dual blockage of HER2 has been widely accepted, after a phase III trial of trastuzumab/docetaxel ± pertuzumab showed the combination to be superior to the monotherapy [1].

Following response to first-line chemotherapy in combination with anti-HER2 treatment, maintenance treatment with an anti-HER2 drug until progression of disease remains currently the standard-of-care. The optimal duration of trastuzumab administration after achieving complete remission of metastatic breast cancer remains, however, unknown. Studies analyzing clinical benefits with trastuzumab in disease beyond progression underline the significant improvements of OS by maintaining the trastuzumab treatment, indicating that progression of disease is not necessarily due to a resistance to trastuzumab [11,12]. In the Royal Marsden experience [13] Waddell et al. provide evidence that trastuzumab continuation beyond progression is of clinical benefit: 59% of the patients with clinical or radiological response achieved a stable disease or better with a median TTP of 24 weeks and a median OS of 19 months. This experience confirms other analysis with patients who received second-line trastuzumab-based chemotherapy for metastatic disease. They achieved a median OS significantly better than those discontinuing trastuzumab at disease progression [14-17,13]

The long term use of trastuzumab raises concerns about cardiotoxicity. An early pivotal trial showed a high incidence of cardiac events under the treatment of trastuzumab, especially when associated with anthracyclines [8]. These adverse effects were mainly reversible. In studies of trastuzumab treatment beyond progression, cardiac events are uncommon and mostly asymptomatic [18,19,11]

After reviewing the published case reports (Table 1) on prolonged complete response following metastatic HER2-amplified disease, it is important to note that in all cases anti-HER2 maintenance treatment has been continued, either with trastuzumab alone [20-23] in combination with pertuzumab [24] or with lapatinib alone [25]. In this last case trastuzumab was stopped at a 2nd progression of disease to achieve a complete remission with lapatinib maintenance therapy [25]. The longest reported relapse free time with trastuzumab maintenance treatment is 8.5 years [22]. So far no case has been published with prolonged complete remission after cessation of anti-HER2 maintenance therapy. All but one case of complete remission describe metastases in the liver. One case describes bone marrow metastases with complete response and long term remission under trastuzumab maintenance treatment [20]. Gene expression studies on response to trastuzumab or lapatinib have shown that HER2-enriched intrinsic profile (ER/PR negative) have higher response rates, as in our case, than HER2 amplified tumors classifying to the luminal intrinsic subtype [26]. Accordingly, in the neoadjuvant setting of HER-2 amplified BC, ER/PR-negativity is an independent predictive marker for response to trastuzumab-based chemotherapy in terms of complete pathological response [27].

Conclusion

Prolonged remission in cases with complete response under trastuzumab based treatment for metastatic HER2-amplified breast cancer are predominantly seen within patients with hormone receptor negative disease and liver metastases, as in the present case. There is no evidence of prolonged complete remission after trastuzumab cessation. Cardiotoxicity has not been reported to be of concern in the presented cases receiving trastuzumab maintenance treatment for more than 5 years.

Consent

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

List of abbreviations

OS: overall survival

HER2: human epidermal growth factor receptor 2

EGFR: epidermal growth factor receptor

MBC: metastatic breast cancer

BC: breast cancer

TTP: time to progression

CHT: chemotherapy

HR: hormone receptor

Figures:

FIGURE 1: Abdomen ultrasound with liver metastases

TABLE 1: Overview of published cases with prolonged complete remission

Case report	Patient's age	HR status	Metastases	CHT with trastuzumab	TTP with trastuzumab maintenance	Trastuzumab maintenance	Follow-up
Present case	81	ER-/PR-	hepatic	paclitaxel and trastuzumab	up to today: 6 years	maintenance	in CR
[23]	34	ER-/PR-	hepatic	vinorelbine, gemcitabine and trastuzumab	up to today: 7 years	maintenance	in CR

[21]	36	ER-/PR-	hepatic	paclitaxel and trastuzumab	3 years	stopped at progression	brain metastases
[22]	46	ER-/PR-	Hepatic and bone	trastuzumab monotherapy	up to today: 8.5 years	maintenance	in CR
[25]	53	ER+/PR-	Hepatic	1 st line: paclitaxel and trastuzumab 2 nd line: capecitabine and lapatinib	17 months 4 years with lapatinib maintenance	stopped at 2 nd progression	in CR with lapatinib alone
[24]	54	ER-/PR-	hepatic	docetaxel, pertuzumab and trastuzumab	up to today: 6 months	trastuzumab and pertuzumab maintenance	in CR
[20]	49	ER+/PR+	bone marrow	paclitaxel, cisplatin and trastuzumab	up to today: 5 years	trastuzumab and letrozole maintenance	in CR

CR: complete remission, TTP: time to progression, CHT: chemotherapy, HR: hormone receptor

Title page

Title

Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: a case report and review of the literature.

Affiliation and address of the authors

Isabel Ihnenfeld Arciénega, Konstantin Dedes, Patrick Imesch, Daniel Fink
UniversitätsSpital Zürich, Zürich, Switzerland

Email addresses and telephone numbers of the authors

isabel.ihnenfeld@usz.ch, +41-44-2551111
konstantin.dedes@usz.ch, +41-44-2551111
patrick.imesch@usz.ch, +41-44-2551111
daniel.fink@usz.ch, +41-44-2551111

Keywords

breast
cancer
metastatic
trastuzumab
HER2

References

1. Swain SM, Kim SB, Cortes J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. The lancet oncology 14 (6):461-471. doi:10.1016/S1470-2045(13)70130-X

2. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM, Group CS (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. *The New England journal of medicine* 366 (2):109-119. doi:10.1056/NEJMoa1113216

3. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ (2006) Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. *Nature clinical practice Oncology* 3 (5):269-280. doi:10.1038/ncponc0509

4. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 28 (1):92-98. doi:10.1200/JCO.2008.19.9844

5. Lobbzoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmoortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, de Boer M, Borm GF, Tjan-Heijnen VC (2013) Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome. *Breast cancer research and treatment* 141 (3):507-514. doi:10.1007/s10549-013-2711-y

6. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science* 235 (4785):177-182

7. Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakhit R, Cardoso F, Peintinger F, Hanrahan EO, Sahin A, Guray M, Larsimont D, Feoli F, Stranzl H, Buchholz TA, Valero V, Theriault R, Piccart-Gebhart M, Ravdin PM, Berry DA, Hortobagyi GN (2009) High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 27 (34):5700-5706. doi:10.1200/jco.2009.23.2025

8. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *The New England journal of medicine* 344 (11):783-792. doi:10.1056/NEJM200103153441101

9. Gradishar WJ (2013) Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 24 (10):2492-2500. doi:10.1093/annonc/mdt217

10. Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R, National Comprehensive Cancer N (2013) Breast cancer, version 3.2013: featured updates to the NCCN guidelines. *Journal of the National Comprehensive Cancer Network : JNCCN* 11 (7):753-760; quiz 761

11. von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, Maartense E, Zielinski C, Kaufmann M, Bauer W, Baumann KH, Clemens MR, Duerr R, Uleer C, Andersson M, Stein RC,

Nekljudova V, Loibl S (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 27 (12):1999-2006. doi:10.1200/JCO.2008.19.6618

12. von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, Maartense E, de Jongh FE, Baumann KH, Bischoff J, Harbeck N, Luck HJ, Maass N, Zielinski C, Andersson M, Stein RC, Nekljudova V, Loibl S, group GBs, participating i (2011) Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. *European journal of cancer* 47 (15):2273-2281. doi:10.1016/j.ejca.2011.06.021

13. Waddell T, Kotsori A, Constantinidou A, Yousaf N, Ashley S, Parton M, Allen M, Starling N, Papadopoulos P, O'Brien M, Smith I, Johnston S (2011) Trastuzumab beyond progression in HER2-positive advanced breast cancer: the Royal Marsden experience. *British journal of cancer* 104 (11):1675-1679. doi:10.1038/bjc.2011.138

14. Campiglio M, Bufalino R, Sandri M, Ferri E, Aiello RA, De Matteis A, Mottolese M, De Placido S, Querzoli P, Jirillo A, Bottini A, Fantini M, Bonetti A, Pedani F, Mauri M, Molino A, Ferro A, Pupa SM, Sasso M, Menard S, Balsari A, Tagliabue E (2011) Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. *Breast cancer research and treatment* 128 (1):147-154. doi:10.1007/s10549-011-1484-4

15. Extra JM, Antoine EC, Vincent-Salomon A, Delozier T, Kerbrat P, Bethune-Volters A, Guastalla JP, Spielmann M, Mauriac L, Misset JL, Serin D, Campone M, Hebert C, Rembliez C, Bergougnoux L, Campana F, Namer M (2010) Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. *The oncologist* 15 (8):799-809. doi:10.1634/theoncologist.2009-0029

16. Fabi A, Metro G, Ferretti G, Giannarelli D, Di Cosimo S, Papaldo P, Mottolese M, Carlini P, Felici A, Russillo M, Cognetti F (2008) Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies. *Breast* 17 (5):499-505. doi:10.1016/j.breast.2008.03.006

17. Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V (2005) Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC). *Onkologie* 28 (11):582-586. doi:10.1159/000088296

18. Fountzilas G, Razis E, Tsavdaridis D, Karina M, Labropoulos S, Christodoulou C, Mavroudis D, Gogas H, Georgoulas V, Skarlos D (2003) Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group. *Clinical breast cancer* 4 (2):120-125

19. Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, Mortimer JE, Murphy M, Stewart SJ (2004) Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 22 (6):1063-1070. doi:10.1200/JCO.2004.06.557

20. Artac M, Koral L, Toy H, Guler T, Boruban MC, Altundag K (2014) Complete response and long-term remission to anti-HER2 combined therapy in a patient with breast cancer presented with bone marrow metastases. *Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners* 20 (2):141-145. doi:10.1177/1078155213480201

21. Beda M, Basso U, Ghiotto C, Monfardini S (2007) When should trastuzumab be stopped after achieving complete response in HER2-positive metastatic breast cancer patients? *Tumori* 93 (5):491-492

22. Macia Escalante S, Rodriguez Lescure A, Pons Sanz V, Martinez Banaclocha N, Guillen Ponce C, Carrato Mena A (2006) A patient with breast cancer with hepatic metastases and a complete response to herceptin as monotherapy. *Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico* 8 (10):761-763

23. Syrios J, Dokou A, Tsavaris N (2010) Sustained complete remission of human epidermal growth factor receptor 2-positive metastatic breast cancer in the liver during long-term trastuzumab (Herceptin) maintenance therapy in a woman: a case report. *Journal of medical case reports* 4:401. doi:10.1186/1752-1947-4-401

24. Schoellhammer HF, Hsu F, Vito C, Chu P, Park J, Waisman J, Kim J (2014) Complete pathologic response of HER2-positive breast cancer liver metastasis with dual anti-HER2 antagonism. *BMC cancer* 14:242. doi:10.1186/1471-2407-14-242

25. Bianchi GV, Duca M, Sica L, Mariani G (2013) Metastatic breast cancer treated with lapatinib with a prolonged benefit: a case report and a review of therapeutic options available. *Tumori* 99 (6):269e-272e. doi:10.1700/1390.15466

26. Montemurro F, Prat A, Rossi V, Valabrega G, Sperinde J, Peraldo-Neia C, Donadio M, Galvan P, Sapino A, Aglietta M, Baselga J, Scaltriti M (2014) Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer. *Molecular oncology* 8 (1):20-26. doi:10.1016/j.molonc.2013.08.013

27. Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kuhn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, von Minckwitz G (2010) Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 28 (12):2024-2031. doi:10.1200/JCO.2009.23.8451